FindTrial
Sign In

Construction of a prediction system for the efficacy of hypofractionated radiotherapy for prostate cancer using artificial intelligence and multimodal MRI

Construction of a prediction system for the efficacy of hypofractionated radiotherapy for prostate cancer using artificial intelligence and multimodal MRI

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071167
Enrollment
Unknown
Registered
2023-05-06
Start date
2022-09-15
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostatic cancer

Interventions

Case series:N/A

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1: T1-4N0M0 prostate cancer patients 2: Biopsy pathological diagnosis of prostate adenocarcinoma, Gleason score 6-10 3: Received radical hypofractionated image-guided IMRT, Dt60Gy/20f or Dt70Gy/28f, etc. 4: Neoadjuvant endocrine therapy 1-3 months before radiotherapy 5: Pelvic MRI including T1, T2, DWI, CE sequence in our hospital before treatment

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
prostate volume;—

Secondary

MeasureTime frame
Pelvic mri;—

Countries

China

Contacts

Public ContactZhong Qiuzi

Beijing Hospital

drzhongqiuzi@163.com+86 13810428903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026